Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Zotatifin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    eFFECTOR, Dana-Farber To Study Zotatifin ER+ Endo/Ovarian Cancer Combo
    eFFECTOR, Dana-Farber To Study Zotatifin ER+ Endo/Ovarian Cancer Combo

    20 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/20/2884841/0/en/eFFECTOR-Therapeutics-to-Collaborate-with-the-Dana-Farber-Cancer-Institute-on-an-Investigator-Sponsored-Phase-2-Clinical-Trial-Evaluating-Zotatifin-as-Combination-Treatment-in-ER-E.html

    GLOBENEWSWIRE
    20 May 2024
    Share Share
    eFFECTOR Therapeutics Announces Data from Phase 2 Expansion Cohorts of Zotatifin
    eFFECTOR Therapeutics Announces Data from Phase 2 Expansion Cohorts of Zotatifin

    08 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/08/2793183/0/en/eFFECTOR-Therapeutics-Announces-New-Positive-Interim-Data-from-Dose-Escalation-and-Phase-2-Expansion-Cohorts-of-Zotatifin-in-ER-Metastatic-Breast-Cancer-Patients.html

    GLOBENEWSWIRE
    08 Dec 2023
    Share Share
    eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin
    eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin

    28 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/28/2786889/0/en/eFFECTOR-Receives-U-S-FDA-Fast-Track-Designation-for-Zotatifin-in-Combination-with-Fulvestrant-and-Abemaciclib-for-Treatment-of-ER-HER2-Advanced-Metastatic-Breast-Cancer.html

    GLOBENEWSWIRE
    28 Nov 2023
    Share Share
    eFFECTOR to Present Data from Phase 2 Expansion Cohorts of Zotatifin
    eFFECTOR to Present Data from Phase 2 Expansion Cohorts of Zotatifin

    15 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/15/2780970/0/en/eFFECTOR-to-Present-New-Clinical-Data-from-Dose-Escalation-and-Phase-2-Expansion-Cohorts-of-Zotatifin-in-Patients-with-ER-Metastatic-Breast-Cancer-at-SABCS-2023-Annual-Meeting.html

    GLOBENEWSWIRE
    15 Nov 2023
    Share Share
    eFFECTOR reports positive data from trial of zotatifin for Covid-19
    eFFECTOR reports positive data from trial of zotatifin for Covid-19

    21 Feb 2023

    // CLINICAL TRIALS ARENA

    https://www.clinicaltrialsarena.com/news/effector-data-trial-zotatifin-covid-19/

    CLINICAL TRIALS ARENA
    21 Feb 2023
    Share Share
    eFFECTOR Therapeutics Announces Results from Phase 1b Trial of Zotatifin
    eFFECTOR Therapeutics Announces Results from Phase 1b Trial of Zotatifin

    21 Feb 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/02/21/2612164/0/en/eFFECTOR-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-1b-Clinical-Trial-of-Zotatifin-for-the-Treatment-of-COVID.html

    GLOBENEWSWIRE
    21 Feb 2023
    Share Share